Mostrar el registro sencillo del ítem

Ivermectin a drug of indiscriminate use in the management of Covid-19

Ivermectina un medicamento de uso indiscriminado en el manejo del Covid-19

dc.creatorAmaya-Aponte, Silvia Camila
dc.date2021-08-20
dc.date.accessioned2022-03-03T21:03:21Z
dc.date.available2022-03-03T21:03:21Z
dc.identifierhttps://revistas.unab.edu.co/index.php/medunab/article/view/4195
dc.identifier10.29375/01237047.4195
dc.identifier.urihttp://test.repositoriodigital.com:8080/handle/123456789/16538
dc.descriptionThe Coronaviridae are a family of RNA viruses that have affected mammals and birds throughout history. These pathogens, known and studied for several decades, have also been responsible for infections that usually occur in the respiratory tract in humans. Its most recent variant SARS-CoV-2, was identified at the end of 2019 in the Chinese city of Wuhan where the virus was identified as the cause of multiple severe pneumonia in the population (1). This outbreak had an extension that exceeded expectations, creating the largest milestone of the 21st century. On March 11, 2020, the virus was declared a pandemic, its direct transmission from person to person played a very important role in the rapid spread of this new coronavirus. Its wide range of clinical presentation, ranging from completely asymptomatic forms to reaching more serious and even fatal respiratory tract infections, never seen before (2), became a social, political and medical challenge.en-US
dc.descriptionLos Coronaviridae son una familia de virus ARN que han afectado, a lo largo de la historia, a mamíferos y aves. Estos patógenos, conocidos y estudiados por varias décadas, también han sido los responsables de infecciones que usualmente se presentan en el tracto respiratorio en humanos. Su más reciente variante SARS-CoV-2, fue identificada a finales del año 2019 en la ciudad china de Wuhan donde el virus fue identificado como el causante de múltiples neumonías severas en la población (1).  Dicho brote tuvo una extensión que superó las expectativas, creando el hito más grande del siglo XXI. El 11 de marzo de 2020 el virus fue declarado pandemia, su transmisión de forma directa de persona a persona jugó un papel muy importante en el rápido esparcimiento de este nuevo coronavirus. Su gran abanico de presentación clínica, que parte desde formas completamente asintomáticas hasta llegar a infecciones de tracto respiratorio más graves e incluso mortales, jamás antes vistas (2), se convirtió en un reto social, político y médico. es-ES
dc.formatapplication/pdf
dc.formattext/xml
dc.languagespa
dc.publisherUNABes-ES
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/4195/3446
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/4195/3467
dc.relation/*ref*/Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to- person transmission: a study of a family cluster. Lancet [Internet]. 2020;395(10223):514–23. doi: http://dx.doi.org/10.1016/S0140-6736(20)30154-9 2. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med [Internet]. 2021;174(1):69–79. doi: https://doi.org/10.7326/M20-5008 3. ZemkovaH,TvrdonovaV,BhattacharyaA,Jindrichova M. Allosteric modulation of ligand gated ion channels by ivermectin. Vol. 63, Physiological Research. 2014. doi: https://doi.org/10.33549/physiolres.932711 4. Banerjee K, Nandy M, Dalai CK, Ahmed SN. The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin. Drug Res (Stuttg). 2020;70(8):337-340. doi: https://doi.org/10.1055/a-1185-8913 5. Instituto Nacional de Vigilancia de Medicamentos y Alimentos - INVIMA. Sistema de Trámites en Línea - Consultas Públicas. 2017. :8082. Available from: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp 6. Schmith VD, Zhou J, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther [Internet]. 2020;108(4):762–5. doi: https://doi.org/10.1002/cpt.1889 7. Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 178, 104787. Antiviral Res [Internet]. 2020;178(January):104787. doi: https://doi.org/10.1016/j.antiviral.2020.104787 8. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. ICON (Ivermectin in Covid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv [Internet]. 2020;(January). doi: https://doi.org/10.1101/2020.06.06.20124461 9. Ortega-Guillén E, Meneses G, Coila E. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study). CHEST J [Internet]. 2020;159(1):2110–1. doi: https://doi.org/10.1016/j.chest.2020.10.088 10. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214– 6. doi: https://doi.org/10.1016/j.ijid.2020.11.191 11. Camprubí D, Almuedo-Riera A, Martí-Soler HI, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020;15(11 November):1–6. doi: https://doi.org/10.1371/journal.pone.0242184 12. Behera P, Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of SARSCoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One [Internet]. 2021;16(2 February):1–12. Available from: http://dx.doi.org/10.1371/journal.pone.0247163 13. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial Visual Abstract Supplemental content. JAMA [Internet]. 2021;325(14):1426–35. Available from: https://jamanetwork.com/ 14. Buonfrate D, Bisoffi Z. Standard Dose Ivermectin for COVID-19. Chest [Internet]. 2021;159(5):2111–2. doi: https://doi.org/10.1016/j.chest.2021.03.003 15. Zangrillo A. COVID-19 y Argumentum ad ignorantiam o «no todo vale». Rev Clínica Española [Internet]. 2020;10(January):19–21. doi: https://doi.org/10.1016/j.rce.2020.04.013
dc.rightsDerechos de autor 2021 MedUNABes-ES
dc.rightshttps://creativecommons.org/licenses/by-nc/4.0es-ES
dc.sourceMedUNAB; Vol. 24 No. 2 (2021): August-November, 2021: Telemedicine, Neoplasms, Cannabis; 151-154en-US
dc.sourceMedUNAB; Vol. 24 Núm. 2 (2021): agosto-noviembre, 2021: Telemedicina, Neoplasias, Cannabis; 151-154es-ES
dc.source2382-4603
dc.source0123-7047
dc.subjectIvermectinen-US
dc.subjectCoronavirus Infectionsen-US
dc.subjectDrug Therapyen-US
dc.subjectPre-Exposure Prophylaxisen-US
dc.subjectComorbidityen-US
dc.subjectIvermectinaes-ES
dc.subjectInfecciones por Coronaviruses-ES
dc.subjectTratamiento Farmacológicoes-ES
dc.subjectProfilaxis Pre-Exposiciónes-ES
dc.subjectComorbilidades-ES
dc.titleIvermectin a drug of indiscriminate use in the management of Covid-19en-US
dc.titleIvermectina un medicamento de uso indiscriminado en el manejo del Covid-19es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem